Amphastar Pharmaceuticals
AMPH
135 hedge funds and large institutions have $421M invested in Amphastar Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 60 increasing their positions, 22 reducing their positions, and 10 closing their positions.
310% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 10
173% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 22
61% more capital invested
Capital invested by funds: $261M → $421M (+$160M)
30% more funds holding
Funds holding: 104 → 135 (+31)
21% less call options, than puts
Call options by funds: $355K | Put options by funds: $448K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$28.7M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$13.7M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$7.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.73M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.71M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$1.03M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$970K |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$956K |
AMPH Hedge Fund Activity: Q3 2016 in Review
135 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2016, worth a combined $421M — up 61% from $261M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AMPH positions and 10 closed out — a net gain of 31 holders — while 60 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $28.7M. The largest seller was Fidelity Investments, cutting an estimated $6.73M.
- 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2016, up from 104 in Q2 2016.
- Funds reported $421M of Amphastar Pharmaceuticals stock for Q3 2016, up 61% quarter-over-quarter.
- 41 funds opened new Amphastar Pharmaceuticals positions in Q3 2016 and 10 closed out, a net change of +31 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $28.7M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2016 was Fidelity Investments, an estimated $6.73M sold.
Based on aggregated 13F filings for Q3 2016.